stockrow
Monday 9 November 2026
Export BBOT’s income statement to Excel — free account
BridgeBio Oncology Therapeutics, Inc
BBOT- EPS
- −25.3%
- Free cash flow
- −88.8%
Quarter to June 2026, against a year earlier
2.04
0.13
−5.99%
Follow BBOT
Alert me
| Dec '25 | Dec '24 | Dec '23 | |
|---|---|---|---|
Current Ratio |
12.34 | 8.10 | — |
Net Debt/EBITDA |
2.93 | 1.93 | — |
Debt/Assets |
0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | — |
Asset Turnover |
0.00 | 0.00 | — |
Operating CF/Net income |
0.85 | 0.74 | — |
Capex/Depreciation |
(0.99) | (0.24) | — |
| (115.33%) | 0.00% | — | |
| (43.76%) | (90.41%) | — | |
ROIC |
0.00% | 0.00% | — |
Return on Tangible Assets |
(33.65%) | (53.20%) | — |
Average Days of Receivables |
0.00 | 0.00 | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | — |
Free Cash Flow per Share |
(3.68) | (4,269.46) | — |
Cash per Share |
13.66 | 12,064.42 | — |
Shareholders Equity per Share |
13.20 | (13,847.83) | — |
Interest Debt per Share |
0.00 | 0.00 | — |
Book value per Share |
13.20 | (13,847.83) | — |
Free Cash Flow |
(114.50) | (55.08) | — |
Working Capital |
397.36 | 139.11 | — |
Capital Expenditures |
(0.61) | (0.05) | — |
Net Current Asset Value |
395.11 | (184.24) | — |
| Other line items | |||
Quick Ratio |
12.15 | 7.95 | — |
Depreciation/Fixed assets |
0.64 | 0.42 | — |
Cash ROIC |
(13.69%) | 239.40% | — |
Accounts Receivable Turnover |
0.00 | — | — |
Accounts Payable Turnover |
0.00 | — | — |
Average Days of Payables |
0.00 | 0.00 | — |
Revenue per Share |
0.00 | 0.00 | — |
Operating CF per Share |
(3.66) | (4,265.66) | — |
Capex per Share |
(0.02) | (3.80) | — |
Average Receivables |
0.23 | — | — |
Average Payables |
2.22 | — | — |
Average Assets |
306.34 | 82.15 | — |
Average Common Equity |
116.23 | — | — |
Capex to Sales |
0.00 | 0.00 | — |
Columns are period end dates · fundamentals updated 26 Oct 2026